drug and therapy bulletin · (cvp) chemotherapy. truxima, which is the first biosimilar to...
TRANSCRIPT
H.P. STATE
COUNCIL
DRUG AND THERAPYBULLETIN
HIMACHAL PRADESH STATE PHARMACY COUNCIL
Toll Free 18001210443
DRUG INFORMATION CENTER
LAUREATE INSTITUTE OF PHARMACY, KATHOG. DISTT. KANGRA. HP. 177101,Toll Free 18001210443 Phone: 09218428042, 9459220253. E-mail: [email protected], [email protected]
Contents |Drug UpdatesPharma NewsPharma Jobs
Continuing Pharmacy Education ProgramLocal News
Which kind of queries can be asked from Drug Information Center?
Issue: 15 ● Volume: 2 ● Dec 2018
DRUG INFORMATION CENTER HIMACHAL PRADESH STATE PHARMACY COUNCIL LAUREATE INSTITUTE OF PHARMACY, KATHOG. DISTT. KANGRA. HP. 177101,
Toll Free 18001210443 Phone: 09218428042, 9459220253. E-mail: [email protected], [email protected]
2
DRUG AND THERAPY BULLETIN
Content
EDITORIAL
Patron
Mr. Gopal Krishan Sharma and Dr. Ran Singh
Editor-in-chief
Dr. Kamlesh Naik and Dr. M.S. Ashawat
Co-Editors
Dr. Vinay Pandit and Mr. Ankush Sharma
Advisory Board
Dr. Navneet Marwah, Mr. Sanjeev Pandit, Dr. Manoj Kumar, Dr. Ranjit Singh, Prof. CPS Verma, Dr. Poonam Sandhu, Dr. Rajender Guleria,
Mr. Arvind Kumar, Mr. Bihari Lal Gupta, Mr, Hemant Sharma, Mr. Rakesh Chandel, Mr. Praveen Upadhya, Mr. Kamashwar Chauhan, Mr.
Lokesh Kumar, Mr. Vishal Kumar, Mr. Y.S.Chandel, Mr. Birbal Sharma, Mr. Manoj Kumar, Mr. Yogesh Verma, Mr. Surender Nadda,
Dr. Parshuram
DRUG UPDATES
Dextenza for Post-op ocular pain ...........................................................................................................4
Xospata for AML for FL T3 mutation ......................................................................................................4
Truxima: First rituxan Biosimilar ............................................................................................................4
stVitrakvi: 1 TRK inhibitor for advanced tumor.........................................................................................4
Venclexta with chemo for AML ..............................................................................................................5
Daurismo with LDAC for AML ...............................................................................................................5
Adcetris with chemotherapy for PTCL.....................................................................................................5
Aemcolo for Traveller’s Diarrhea ............................................................................................................5
Keytruda now approved for HCC............................................................................................................5
stYupelri: 1 Nebulized bronchodilator for COPD .......................................................................................6
New Emplicicti for combo for MM .........................................................................................................6
3
DRUG INFORMATION CENTER HIMACHAL PRADESH STATE PHARMACY COUNCIL LAUREATE INSTITUTE OF PHARMACY, KATHOG. DISTT. KANGRA. HP. 177101,
Toll Free 18001210443 Phone: 09218428042, 9459220253. E-mail: [email protected], [email protected]
Udenyca: Second neulasta biosimilar .....................................................................................................6
PHARMA NEWS
Chandigarh: Government suspends license of 1,000 chemists in 10 months ..............................................7
Jan Aushadhi shops can replace branded drugs with generics ...................................................................7
Future of Homeopathy lies in standardization ..........................................................................................7
Government plans database of drugs to prevent use of similar brand names ...............................................8
Probiotics not beneficial for young kids with stomach virus .......................................................................8
Antibiotic resistance kills over 50,000 children in India annually...............................................................9
Weightlifting may be good for your heart: Study ......................................................................................9
Disabling and potentially permanent side effects lead to suspension or restrictions of quinolone and
fluoroquinolone antibiotics: EMA ...........................................................................................................9
MoU signed on India-UK Cancer Research Initiative for Affordable Approaches to Cancer...........................10
PHARMA JOBS
Walk in interview for Research Associate at IHBT ..................................................................................11
CSIR Project(s): “Bioprospection of Microbiome from Himalayan Niches.” ................................................11
CSIR Project(s): “Conservation and sustainable resource generation of high altitude bioresources
at CSIR-Centre for High Altitude Biology (NCP)" ....................................................................................11
CONTINUING PHARMACY EDUCATION PROGRAMME
Continuing Pharmacy Education Programme (CPE) for Pharmacy Teachers...............................................12
Continuing Pharmacy Education Programme.........................................................................................12
LOCAL NEWS
Newspaper – Amar Ujala, 30-11-2018................................................................................................13
Newspaper – Amar Ujala, 28-11-2018................................................................................................13
Newspaper – Amar Ujala, 21-11-2018................................................................................................14
Content (Continued)
DRUG INFORMATION CENTER HIMACHAL PRADESH STATE PHARMACY COUNCIL LAUREATE INSTITUTE OF PHARMACY, KATHOG. DISTT. KANGRA. HP. 177101,
Toll Free 18001210443 Phone: 09218428042, 9459220253. E-mail: [email protected], [email protected]
4
DRUG AND THERAPY BULLETIN
DRUG UPDATES
Dextenza for Post-op ocular pain
On December 3, 2018, the US FDA approved
®Dextenza (dexamethasone) ophthalmic extended-
release implant for intracanalicular use indicated for the
treatment of ocular pain following ophthalmic surgery.
Dextenza, which is the first intracanalicular implant to
gain FDA approval, delivers dexamethasone for up to 30
days following a single administration.
Prescribing information can be found at: http://www.
dextenza.com/wp-content /uploads/2018/12/
DEXTENZA-Final-Label-12.1.18.pdf.
Xospata for AML for FL T3 mutation
On November 28, 2018, the US FDA approved
®Xospata (gilteritinib) oral tablets indicated to treat adult
patients who have relapsed or refractory acute myeloid
leukemia (AML) with a FLT3 mutation as detected by an
FDA-approved test. Xospata, which was granted fast
track, priority review, and orphan drug designations, was
approved based on a clinical trial demonstrating a
significant rate of complete remission or complete
remission with partial hematologic recovery in patients
treated with gilteritinib.
Prescribing information can be found at: https://www.
accessdata.fda.gov/drugsatfda_docs/label/2018/2113
49s000lbl.pdf.
Truxima: First rituxan Biosimilar
On November 28, 2018, the US FDA approved
®Truxima (rituximab-abbs) IV injection indicated to treat
adult patients with: 1) relapsed or refractory, low-grade
or follicular, CD20-positive, B-cell non-Hodgkin
lymphoma (NHL) as a single agent; 2) previously
untreated follicular, CD20-positive, B-cell NHL in
combination with first line chemotherapy and, in
patients achieving a complete or partial response to a
rituximab product in combination with chemotherapy, as
single-agent maintenance therapy; and 3) non-
progressing (including stable disease), low-grade,
CD20-positive, B-cell NHL as a single agent after first-
line cyclophosphamide, vincristine, and prednisone
(CVP) chemotherapy. Truxima, which is the first
biosimilar to Rituxan(R) (rituximab) to gain FDA
approval, was approved based on pharmacokinetic,
clinical immunogenicity, and other clinical data
demonstrating that rituximab-abbs is biosimilar to
rituximab.
Prescribing information can be found at: https://www.
accessdata.fda.gov/drugsatfda_docs/label/2018/7610
88s000lbl.pdf.
stVitrakvi: 1 TRK inhibitor for advanced tumor
On November 26, 2018, the US FDA approved
®Vitrakvi (larotrectinib) oral capsules and oral solution
indicated to treat adult and pediatric patients with solid
tumors that have a neurotrophic receptor tyrosine kinase
(NTRK) gene fusion without a known acquired resistance
mutation, are metastatic or where surgical resection is
likely to result in severe morbidity, and have no
satisfactory alternative treatments or that have
progressed following treatment. Vitrakvi, which is the
first tyrosine receptor kinase (TRK) inhibitor to gain FDA
approval, was approved based on pooled data from 3
clinical trials in which larotrectinib demonstrated a 75%
overall response rate across different types of solid
tumors.
Prescribing information can be found at: https://www.
accessdata.fda.gov/drugsatfda_docs/label/2018/2108
61s000lbl.pdf.
5
DRUG INFORMATION CENTER HIMACHAL PRADESH STATE PHARMACY COUNCIL LAUREATE INSTITUTE OF PHARMACY, KATHOG. DISTT. KANGRA. HP. 177101,
Toll Free 18001210443 Phone: 09218428042, 9459220253. E-mail: [email protected], [email protected]
Venclexta with chemo for AML
On November 21, 2018, the US FDA approved a new
®indication for Venclexta (venetoclax) oral tablets in
combination with azacitidine or decitabine or low-dose
cytarabine for the treatment of newly-diagnosed acute
myeloid leukemia (AML) in adults who are 75 years of
age or older, or who have comorbidities that preclude use
of intensive induction chemotherapy. Venclexta, which
was approved under priority review for this indication,
demonstrated efficacy based on the rate and duration of
complete remission in 2 clinical trials.
Prescribing information can be found at : https://www.
accessdata.fda.gov/drugsatfda_docs/label/2018/2085
73s009lbl.pdf.
Daurismo with LDAC for AML
On November 21, 2018, the US FDA approved TMDaurismo (glasdegib) oral tablets in combination with
low-dose cytarabine (LDAC), for the treatment of newly-
diagnosed acute myeloid leukemia (AML) in adult
patients who are 75 years of age or older or who have
comorbidities that preclude use of intensive induction
chemotherapy. In a clinical trial, patients treated with
glasdegib plus LDAC demonstrated a significantly
greater improvement in overall survival compared with
those treated with LDAC alone. Daurismo carries a boxed
warning regarding the potential for embyro-fetal toxicity,
including embryo-fetal death and severe birth defects.
Prescribing information can be found at https://www.
accessdata.fda.gov/drugsatfda_docs/label/2018/2106
56s000lbl.pdf.
Adcetris with chemotherapy for PTCL
On November 16, 2018, the US FDA approved a new
®indication for Adcetris (brentuximab vedotin) IV
injection to treat adult patients with previously untreated
systemic anaplastic large cell lymphoma (sALCL) or
other CD30-expressing peripheral T-cell lymphomas
(PTCL), including angioimmunoblastic T-cell lymphoma
and PTCL not otherwise specified, in combination with
cyclophosphamide, doxorubicin, and prednisone.
Adcetris, which was granted breakthrough therapy and
priority review designations by the FDA, was approved
for this indication based on data from the Echelon-2
clinical trial. This marks the first FDA approval for
treatment of newly diagnosed PTCL.
Prescribing information can be found at : https://www.
adcetrispro.com/pi.
Aemcolo for Traveller’s Diarrhea
On November 16, 2018, the US FDA approved TMAemcolo (rifamycin) oral delayed-release tablets to
treat adult patients with travelers' diarrhea caused by
noninvasive strains of Escherichia coli, not complicated
by fever or blood in the stool. Aemcolo, which was
granted the Qualified Infectious Disease Product
designation by the FDA, demonstrated efficacy in a
clinical trial in which rifamycin significantly reduced
symptoms of travelers' diarrhea compared with placebo.
Prescribing information can be found at http://www.
ariespharma.com/wp-content/ uploads/2018/11/1-
AEM18176-NDA-210910-Approved-PI-11-16-18.pdf.
Keytruda now approved for HCC
On November 9, 2018, the US FDA approved
®Keytruda (pembrolizumab) IV injection indicated to
treat patients with hepatocellular carcinoma (HCC) who
have been previously treated with sorafenib. Keytruda,
which was granted accelerated approval for this
indication, demonstrated efficacy with a significant
overall response rate following treatment with
pembrolizumab in the KEYNOTE-224 trial.
DRUG INFORMATION CENTER HIMACHAL PRADESH STATE PHARMACY COUNCIL LAUREATE INSTITUTE OF PHARMACY, KATHOG. DISTT. KANGRA. HP. 177101,
Toll Free 18001210443 Phone: 09218428042, 9459220253. E-mail: [email protected], [email protected]
6
DRUG AND THERAPY BULLETIN
Pre s c r i b i n g i n f o rma t i on can be f ound a t :
https://www.accessdata.fda.gov/drugsatfda_docs/label/
2018/125514s042lbl.pdf.
stYupelri: 1 Nebulized bronchodilator for COPD
TMOn November 9, 2018, the US FDA approved Yupelri
(revefenacin) inhalation solution indicated for the
maintenance treatment of patients with chronic
obstructive pulmonary disease (COPD). Yupelri, which is
the first once-daily bronchodilator to gain approval for
COPD, demonstrated efficacy in a clinical trial in which
patients treated with revefenacin had significant
improvements in trough forced expiratory volume
compared with those treated with placebo.
Prescribing information can be found at: https://www.
accessdata.fda.gov/drugsatfda_docs/label/2018/2105
98s000lbl.pdf.
New Emplicicti for combo for MM
®On November 6, 2018, the US FDA approved Empliciti
(elotuzumab) IV injection for use in combination with
pomalidomide and dexamethasone for the treatment of
adult patients with multiple myeloma (MM) who have
received at least 2 prior therapies, including
lenalidomide and a proteasome inhibitor. Following
priority review, Empliciti was approved for this indication
based on clinical trials in which patients treated with
elotuzumab in combination with pomalidomide and
dexamethasone experienced significantly reduced
disease progression compared with those treated with
pomalidomide and dexamethasone.
Prescribing information can be found at: http://
packageinserts.bms.com/pi/pi_empliciti.pdf.
Udenyca: Second neulasta biosimilar
On November 2, 2018, the US FDA approved TMUdenyca (pegfilgrastim-cbqv) subQ injection indicated
to decrease the incidence of infection, as manifested by
febrile neutropenia, in patients with non-myeloid
malignancies receiving myelosuppressive anti-cancer
drugs associated with a clinically significant incidence of
febrile neutropenia. Udenyca, which is the second
biosimilar to Neulasta(R) (pegfilgrastim) to gain FDA
approval, was approved based on similarity to the
reference drug and pharmacokinetic, pharmaco-
dynamic, and immunogenicity studies.
Prescribing information can be found at: https://www.
accessdata.fda.gov/drugsatfda_docs/label/2018/7610
39s000lbl.pdf
Reference: www.micromedex.com
7
DRUG INFORMATION CENTER HIMACHAL PRADESH STATE PHARMACY COUNCIL LAUREATE INSTITUTE OF PHARMACY, KATHOG. DISTT. KANGRA. HP. 177101,
Toll Free 18001210443 Phone: 09218428042, 9459220253. E-mail: [email protected], [email protected]
PHARMA NEWS
Chandigarh: Government sus-
pends license of 1,000 chemists in 10 months
In its fight against drugs, the Punjab government has
tightened the noose around chemists indulging in
malpractices by suspending licenses of nearly 1,000
shops in the last 10 months. There are nearly 16,000
retail and 8,000 wholesale chemists across the state. A
large number of them have come up in recent years,
especially in rural areas. And these reportedly indulge in
illegal activities such as sale of habit-forming drugs.
From January to October, 8,024 inspections were
conducted and actions against the violators were
initiated under the provisions of the Drugs and Cosmetics
Act, 1940 / Rules 1945. Ninety licenses were
suspended and 12 cancelled due to contraventions
relating to habit-forming drugs. While remaining licenses
were suspended due to general violation, which include
non-availability of pharmacist. According to the drugs
and cosmetic rules, every chemist must have a
pharmacist. However, throwing norms to the winds, a
large number of these shops operate without a
pharmacist. Many were found without proper records
too.
Ref: www.healtheconomics.indiatimes.com
Jan Aushadhi shops can replace branded
drugs with generics
To promote low-cost generic medicines, the
government's top drug regulatory board has allowed Jan
Aushadhi Kendras — which are like fair price shops for
medicines under the Pradhan Mantri Bhartiya
Janaushadhi Pariyojana — to substitute doctor's
prescription with a generic brand. The Drugs Technical
Advisory Board cleared a proposal to amend a rule under
the drugs law. “This proposal asking permission for
chemists to substitute brands prescribed by doctors with
other brands was pending for a very long time. For the
time being, we have allowed only Jan Aushadhi stores to
do so because we want to watch it on a trial basis,” an
official said. So far, chemists were legally not allowed to
replace the brand or the medicine prescribed by a doctor.
The official said allowing all retailers to substitute
medicine brands may open up the market to corruption
as chemists may push brands with higher margin. The
move is also likely to promote Jan Aushadhi stores which
have failed to take off as well as intended in the last few
years. At present, there are over 4,000 Jan Aushadhi
stores.
Ref: www.healtheconomics.indiatimes.com
Future of Homeopathy lies in standardization
Homeopathy has survived the last 200 years despite
opposition from many quarters and is slowly emerging as
the largest system of medicine patronized by
governments and people alike due to safety, efficacy and
standardization of homeopathic practices. From being an
alternative system of medicine, homeopathy has become
a complementary system of medicine and a primary
healthcare choice to treat both acute and chronic
medical conditions. People including allopathic doctors
DRUG INFORMATION CENTER HIMACHAL PRADESH STATE PHARMACY COUNCIL LAUREATE INSTITUTE OF PHARMACY, KATHOG. DISTT. KANGRA. HP. 177101,
Toll Free 18001210443 Phone: 09218428042, 9459220253. E-mail: [email protected], [email protected]
8
DRUG AND THERAPY BULLETIN
are accepting homeopathy like never before. From a
humble beginning with just 200 drugs during
Hahnemann's time, today there are more than
2,000clinically-tested homeopathic medicines in
practice. Its growing popularity can be gauged from the
fact that World Health Organization has recognized it as
the second largest system of medicine in the world. For
the past 250 years, this system of medicine has made a
remarkable journey and has a bright future across the
world. There are multiple factors that have lead to a
resurgence of homeopathy globally. First, thanks to
standardization that is happening at a rapid pace in
developed countries, homeopathy is coming on par with
allopathic medicines. Homeopathy drugs are now pre
medicated, prepackaged, sealed, and labeled which is
proving to be a boon for patients. New packaging tubes
are made of food grade plastic and dispensing has
become hygienic and easier using modern technology.
The trend has just begun and is rapidly catching up.
Ref: www.healtheconomics.indiatimes.com
Government plans database of drugs to
prevent use of similar brand names
The government is considering a databank for all
medicine brands to prevent pharmaceutical companies
from using the same or similar looking and sounding
brand names for drugs, especially those used to treat
different conditions, senior officials close to the
development said. The Drugs Technical Advisory Board
(DTAB), the country's highest drug advisory body, will
discuss a mechanism to this effect at its meeting because
the problem is extensive and spread across the country.
Ref: www.healtheconomics.indiatimes.com
Probiotics not beneficial for young kids with
stomach virus
Children with stomach viruses are often given probiotics
to ease symptoms of vomiting and diarrhea. However, a
new study has found that commonly used probiotic is not
effective in improving symptoms in young patients
with gastroenteritis. The study was led by Washington
University School of Medicine in St. Louis and the
results were published in The New England Journal of
Medicine.
"Probiotics have become an increasingly popular way to
treat children experiencing acute gastroenteritis. Some
smaller studies have indicated that probiotics may help,
however, such studies had a number of limitations. We
sought to provide independent and conclusive evidence
for or against probiotic use in infants and toddlers with
acute gastroenteritis," said the study author David
Schnadower.
“Probiotics had no effect on the children. Parents are
better off saving their money and using it to buy more
fresh fruits and vegetables for their children,” said US
study co-author Phillip I. Tarr. There are no treatments for
pediatric acute gastroenteritis other than giving children
fluids to prevent dehydration and, sometimes,
medication to relieve nausea. The lack of options has
prompted some physicians and parents to give ill
children probiotics.
Probiotics generally are considered safe. However, the
Food and Drug Administration (FDA) does not regulate
9
DRUG INFORMATION CENTER HIMACHAL PRADESH STATE PHARMACY COUNCIL LAUREATE INSTITUTE OF PHARMACY, KATHOG. DISTT. KANGRA. HP. 177101,
Toll Free 18001210443 Phone: 09218428042, 9459220253. E-mail: [email protected], [email protected]
dietary supplements such as probiotics as stringently as
it does prescription and over-the-counter drugs.
"Because of the popularity of probiotics, it was important
to make sure their use is worth the cost. In this instance,
probiotics added no measurable benefit, and, therefore,
they are not worth the added cost," said Schnadower.
Ref: www.healtheconomics.indiatimes.com
Antibiotic resistance kills over 50,000
children in India annually
Antibiotic-resistant infections are spreading wings in
India, killing over 58,000 children every year, while
uncontrolled dumping of untreated urban waste into
water bodies is affecting aquatic life and environment.
With some of the highest antibiotic resistant bacteria
that commonly cause infections in the community and
healthcare facilities, India suffers severely, reminds
Centre for Disease Dynamics Economics and Policy
(CDDEP), as World Antibiotic Awareness Week 2018.
"Every year globally, almost 700,000 lives are lost. More
than 58,000 children die every year in India alone, from
antibiotic-resistant infections," said CDDEP. The
antibiotic resistance is the ability of disease-causing
bacteria and micro-organisms to resist the antibiotics or
medicine due to adaptation.
Ref: www.healtheconomics.indiatimes.com
Weightlifting may be good for your heart: Study
Lifting weights for less than an hour a week may reduce
your risk for a heart attack or stroke by 40 to 70 per cent,
a study has found. The research by Iowa State University
(ISU) in the US also showed that spending more than an
hour in the weight room did not yield any additional
benefit. "People may think they need to spend a lot of
time lifting weights, but just two sets of bench presses
that take less than 5 minutes could be effective," said
Duck-chul Lee, associate professor at Iowa State
University (ISU). You do not have to meet the
recommended guidelines for aerobic physical activity to
lower your risk; weight training alone is enough.
Ref: www.healtheconomics.indiatimes.com
Disabling and potentially permanent side
effects lead to suspension or restrictions of
quinolone and fluoroquinolone antibiotics: EMA
EMA has reviewed serious, disabling and potentially
permanent s ide ef fects wi th quinolone and
fluoroquinolone antibiotics given by mouth, injection or
DRUG INFORMATION CENTER HIMACHAL PRADESH STATE PHARMACY COUNCIL LAUREATE INSTITUTE OF PHARMACY, KATHOG. DISTT. KANGRA. HP. 177101,
Toll Free 18001210443 Phone: 09218428042, 9459220253. E-mail: [email protected], [email protected]
DRUG AND THERAPY BULLETIN
10
inhalation. The review incorporated the views of
patients, healthcare professionals and academics
presented at EMA's public hearing on fluoroquinolone
and quinolone antibiotics in June 2018. EMA's human
medicines committee (CHMP) has endorsed the
recommendations of EMA's safety committee (PRAC)
and concluded that the marketing authorisation of
medicines containing cinoxacin, flumequine, nalidixic
acid, and pipemidic acid should be suspended.
The CHMP confirmed that the use of the remaining
fluoroquinolone antibiotics should be restricted. In
addition, the prescribing information for healthcare
professionals and information for patients will describe
the disabling and potentially permanent side effects and
advise patients to stop treatment with a fluoroquinolone
antibiotic at the first sign of a side effect involving
muscles, tendons or joints and the nervous system.
Ref: www.pharmatutor.org
MoU signed on India-UK Cancer Research
Initiative for Affordable Approaches to Cancer
A Memorandum of Understanding (MoU) for the
partnership between Department of Biotechnology and
Cancer Research UK for the India-UK India-UK Cancer
Research Initiative was signed in New Delhi.
The India-UK Cancer Research Initiative is a
collaborative 5-year bilateral research initiative by the
Department of Biotechnology, Ministry of Science &
Technology, India and Cancer Research UK (CRUK) that
will focus on affordable approaches to cancer. Both
CRUK and DBT will invest £5m each in this 5-year pilot,
and seek further investment from other potential funding
partners.
The India-UK Cancer Research Initiative will identify a
core set of research challenges that address issues of
affordability, prevention and care of cancer by bringing
together leading Indian and UK experts across clinical
research, demographic research, new technologies and
physical sciences. The initiative will provide funding to
develop new research alliances and undertake impactful
research to enable significant progress against cancer
outcomes.
Ref: www.pharmatutor.org
Reference: www.micromedex.com
DRUG INFORMATION CENTER HIMACHAL PRADESH STATE PHARMACY COUNCIL LAUREATE INSTITUTE OF PHARMACY, KATHOG. DISTT. KANGRA. HP. 177101,
Toll Free 18001210443 Phone: 09218428042, 9459220253. E-mail: [email protected], [email protected]
11
PHARMA JOBS
Walk in interview for Research Associate at IHBT
Eligible candidates may appear for “Walk-in-interview(s)” on the dates, time and place mentioned below along with
an application on prescribed format which is available on the CSIR-IHBT website ihbt.res.in along with attested
photocopies of their testimonials of age, educational qualifications, experience, reserved category etc. at the time of
interview. The positions are purely temporary and co-terminus with the duration of the project. There will be no
right implicit or explicit for regular position or any post in CSIR-IHBT, whatsoever. Candidates must also bring with
them original certificates of testimonials at the time of appearing for the interview failing which he/she will not be
allowed to appear for interview. No TA will be paid for attending the interview.
CSIR Project(s): “Bioprospection of Microbiome from Himalayan Niches.”
Research Associate – 01 post
Maximum Age(As on date of interview): 35 years as on 14-12-2018
Stipend (Per Month) [Consolidated]: Rs. 38,000/- p.m. + HRA
Educational Qualification(s) Essential:
Ph.D. in Biotechnology / Microbiology with two years working experience in the area of Microbial genomics.
Tenure of the Project(s): 31-03-2020
CSIR Project(s): “Conservation and sustainable resource generation of high altitude bio-
resources at CSIR-Centre for High Altitude Biology (NCP)"
Research Associate – 04 posts
Maximum Age (As on date of interview): 35 years as on 14-12-2018
Stipend (Per Month) [Consolidated]: Rs. 36,000/- p.m. + HRA
Educational Qualification(s) Essential:
Ph.D. in Biotechnology / Forestry / Botany.
Tenure of the Project(s): 31-03-2020
DRUG INFORMATION CENTER HIMACHAL PRADESH STATE PHARMACY COUNCIL LAUREATE INSTITUTE OF PHARMACY, KATHOG. DISTT. KANGRA. HP. 177101,
Toll Free 18001210443 Phone: 09218428042, 9459220253. E-mail: [email protected], [email protected]
DRUG AND THERAPY BULLETIN
12
Continuing Pharmacy Education Programme
Himachal Pradesh State Pharmacy Council is organinzing first ‘Continuing Pharmacy Education Programme’ for
the registered pharmacist of District Bilaspur (2018-2022) at Shiva Institute of Engineering and Technology,
Chandpur, Bilaspur on 16th December 2018. All the pharmacists of District Bilaspur are informed to participate in
the said programme.
CPE Programme
Continuing Pharmacy Education Programme (CPE) for Pharmacy Teachers
First PCI sponsored CPE of Himachal Pradesh, for Pharmacy teachers, is organizing at Laureate Institute of
Pharmacy Kathog, Jwalamukhi, HP from 6th to 8th January 2019. Thirty (30) participants from different PCI
approved pharmacy institutions and University departments of this region (Himachal Pradesh, Punjab, Haryana,
Chandigah and Rajasthan) can participate in this CPE. Interested members can fill the registration form which
can be downloaded from the web site www.laureateinstitutes.in before 20-12-2018. Registration will be on first
come first serve basis.
DRUG INFORMATION CENTER HIMACHAL PRADESH STATE PHARMACY COUNCIL LAUREATE INSTITUTE OF PHARMACY, KATHOG. DISTT. KANGRA. HP. 177101,
Toll Free 18001210443 Phone: 09218428042, 9459220253. E-mail: [email protected], [email protected]
13
LOCAL NEWSPAPERS
Reference:
Amar Ujala, 30-11-2018
Reference:
Amar Ujala, 28-11-2018
DRUG INFORMATION CENTER HIMACHAL PRADESH STATE PHARMACY COUNCIL LAUREATE INSTITUTE OF PHARMACY, KATHOG. DISTT. KANGRA. HP. 177101,
Toll Free 18001210443 Phone: 09218428042, 9459220253. E-mail: [email protected], [email protected]
DRUG AND THERAPY BULLETIN
14
Reference:
Amar Ujala, 21-11-2018
Which kind of queries can be asked from Drug
Information Center?
It is the matter of pride for all the population of Himachal
Pradesh that there is drug information center (DIC) in the
state which is giving the services to promote the rational
drug use. Maximum population of state knows that there is
DIC, but they are unaware about the services of the DIC.
They all are confused that which kind of queries they can ask.
There is no any restriction to take the drug query
information by any one. Any person (physician, pharmacist,
nurse, patient, people of community, old persons, students,
researchers etc.) can come in or call in the DIC office to take
drug information.
Following kinds of queries regarding drugs can be asked
from DIC:
Ÿ If patient is administering two medicines at the same
time then he/she before administering the medicine,
can confirm from DIC that this combination is safe or not
safe. If combination will be not safe then it may also be
life threatening.
Ÿ If patient is administering a medicine then he/she can
confirm which kinds of foods have to be avoided.
Ÿ Someone can confirm that use of any specific medicine
in particular condition (like as pregnancy/lactation) is
safe or not safe.
Ÿ General information about drug identification can also
be taken from the DIC, like as use and side/adverse
effects , t ime of administrat ion, durat ion of
administration, dose in different age groups etc. about
any drug.
Ÿ Information about substituted drugs with different
prices can also be provided by DIC.
Ÿ Any updation about medicines can be confirmed from
DIC.
DIC will provide the accurate information on request
without any fear and favor. In short, we can say that DIC can
provide any kind of information about any medicine to
anyone without any cost. Personnel can assess directly, can
call in the DIC office, sent the query by post, by E-mail
DRUG INFORMATION CENTER HIMACHAL PRADESH STATE PHARMACY COUNCIL LAUREATE INSTITUTE OF PHARMACY, KATHOG. DISTT. KANGRA. HP. 177101,
Toll Free 18001210443 Phone: 09218428042, 9459220253. E-mail: [email protected], [email protected]
15
Toll Free 18001210443, Phone: 09218428042, 9459220253
Scan this Quick Response (QR)
code to know more
You may download any QR code scanner from
Play Store/iTunes
Personnel can assess directly, can call in the DIC office, sent the query by post, by E-mail on following address.
Note: If any want to publish his/her article in the monthly bulletin of Drug Information Center regarding Pharma updates, they can send their articles with their full address and professional status on the following reference before 25th of every month.
Toll Free 18001210443
DRUG INFORMATION CENTER
HIMACHAL PRADESH STATE PHARMACY COUNCIL
Laureate Institute of Pharmacy, Kathog, Jwala Ji, Distt. Kangra HP 177101
Website: www.hpspc.in | Mail ID: [email protected], [email protected]